Specifically, aBMSCs increased the expression of the IRS-1 gene, resulting in enhanced insulin sensitivity, whereas, aBM-MNCs improved glucagon-stimulated C-peptide response during hyperglycemic clam, providing newer insights in T2D cell-based therapy. The gene discussed is GCG; the disease is type 2 diabetes mellitus.